Windjammer Capital Investors (“Windjammer”), a national private equity investment firm focused on control equity investments in middle-market businesses, has announced the acquisition of Bio X Cell, LLC (“BXC” or the “Company”) in partnership with management. Bio X Cell is a leading producer of monoclonal antibodies (mAbs) for use in both in vivo and in vitro pre-clinical research applications. Founded by Dr. Klaus Lubbe in 1997 as a contract manufacturer of antibodies, BXC has evolved to become the only pure-play in vivo mAbs manufacturer of scale, providing “off-the-shelf”, ultra-pure, low endotoxin antibodies.
Read the full article: Windjammer Capital Acquires Bio X Cell //
Source: https://www.prnewswire.com/news-releases/windjammer-capital-acquires-bio-x-cell-302014165.html